COVID-19 Statement from the CEO

first and foremost, our concern is for the safety and health of our employees and their families, as well as for that of our customers and partners. Fundamentally, Bruker contributes, indirectly or directly, in important ways to global healthcare, food supply, IT infrastructure, and homeland security.

We support many customers in their important research and development, analytical and diagnostic testing, as well as product safety and quality assurance, which are and will remain a high priority for our societies. Finally, Bruker continues to have a solid balance sheet and a strong liquidity position.

With our enabling life science and diagnostic tools, we are particularly pleased to provide essential research and service support for infectious disease research, for anti-viral vaccine and therapeutic drug discovery and development, as well as for clinical microbiology and viral testing in support of the fight against the COVID-19 pandemic.

Our clinical microbiology solutions are key for early identification of bacterial or fungal diseases that can affect COVID-19 patients with weakened immune systems, who may be also suffering from pneumonia or hospital-acquired complications.

With best regards,

Dr. Frank Laukien

CEO and President of Bruker Corporation